Related Experiment Video
Updated: May 28, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing.
Jerry Zhou1, Larissa Belov, Michael J Solomon
1School of Molecular Bioscience, University of Sydney. j.zhou@uws.edu.au
Journal of Visualized Experiments : Jove
|October 5, 2011
Summary
This study introduces a novel DotScan CRC antibody microarray for surface proteome profiling of colorectal cancer cells. This method offers a potential diagnostic alternative to current staging systems for improved cancer prognostication.
Area of Science:
- Oncology
- Biomarker Discovery
- Proteomics
Background:
- Current colorectal cancer (CRC) prognosis relies on histopathologic and clinical staging, which may not capture the complexity of mutations driving cell dysfunction.
- While cell surface antigens are promising biomarkers, no single marker has surpassed current staging systems for routine CRC prognostication.
- Existing proteomic techniques for biomarker discovery are often unsuitable for routine diagnostics due to sample requirements and inability to differentiate cell types.
Purpose of the Study:
- To describe a simple and effective method for surface proteome profiling of viable colorectal cancer cells.
- To present the DotScan CRC antibody microarray as a tool for identifying prognostic biomarkers.
- To propose this method as a potential alternative to current CRC staging systems.
Main Methods:
- Development of the DotScan CRC antibody microarray, featuring 122 antibodies for leukocyte markers, adhesion molecules, receptors, inflammation markers, and 40 CRC-specific prognostic markers.
- Utilizing the microarray to profile surface antigens on viable cells from disaggregated CRC samples.
- Employing fluorescence multiplexing to analyze specific cell subpopulations, such as CRC cells (EpCAM) and T-cells (CD3).
Main Results:
- The DotScan CRC antibody microarray enables surface proteome profiling of viable cells from CRC samples.
- Cell density on the array reflects antigen expression levels and cell proportion.
- The method allows for immunophenotyping of mixed cell populations and analysis of specific subpopulations.
Conclusions:
- The DotScan CRC antibody microarray provides a novel approach for surface proteome profiling in colorectal cancer.
- This technique has the potential to serve as a diagnostic alternative to traditional staging systems.
- Further development could lead to improved prognostic stratification and personalized treatment strategies for CRC patients.
